Fibricor Vial
Fibricor Vial Uses, Dosage, Side Effects, Food Interaction and all others data.
Fibricor Vial is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
Fibricor Vial prolongs the action potential duration and increases both atrial and ventricular refractoriness in vivo, i.e., class III electrophysiologic effects. Voltage clamp studies indicate that ibutilide, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act.
Trade Name | Fibricor Vial |
Availability | Prescription only |
Generic | Ibutilide |
Ibutilide Other Names | Ibutilid, Ibutilida, Ibutilide, Ibutilidum |
Related Drugs | propranolol, Xarelto, diltiazem, digoxin, rivaroxaban, sotalol, flecainide, propafenone, Multaq, esmolol |
Weight | 0.1mg |
Type | Injection |
Formula | C20H36N2O3S |
Weight | Average: 384.576 Monoisotopic: 384.244663718 |
Protein binding | 40% |
Groups | Approved |
Therapeutic Class | |
Manufacturer | Zuventus Health Care Ltd |
Available Country | India |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Fibricor Vial is a class III antiarrhythmic agent used to correct atrial fibrillation and atrial flutter, which can be considered as an alternative to cardioversion.
Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Fibricor Vial is also used to associated treatment for these conditions: Atrial Fibrillation, Flutter, Atrial
How Fibricor Vial works
Fibricor Vial is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca2+ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K+ current, by binding within potassium channel pores. In other words, Fibricor Vial binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels
Toxicity
Acute overdose in animals results in CNS toxicity; notably, CNS depression, rapid gasping breathing, and convulsions. The intravenous median lethal dose in the rat was more than 50 mg/kg which is, on a mg/m2 basis, at least 250 times the maximum recommended human dose.
Food Interaction
No interactions found.Fibricor Vial Drug Interaction
Unknown: ramipril, ramipril, trolamine salicylate topical, trolamine salicylate topical, lorazepam, lorazepam, ipratropium, ipratropium, amoxicillin / clavulanate, amoxicillin / clavulanate, dutasteride, dutasteride, insulin glargine, insulin glargine, acetaminophen, acetaminophen, metoclopramide, metoclopramide, rivaroxaban, rivaroxaban
Fibricor Vial Disease Interaction
Major: cardiovascular dysfunction, proarrhythmic effectsModerate: electrolyte imbalance, hepatic/renal
Volume of Distribution
- 11 L/kg
Elimination Route
Rapid after intravenous injection
Half Life
6 hours (ranges from 2-12 hours)
Clearance
- 29 mL/min/kg
Elimination Route
In healthy male volunteers, about 82% of a 0.01 mg/kg dose of [14C] ibutilide fumarate was excreted in the urine (about 7% of the dose as unchanged ibutilide) and the remainder (about 19%) was recovered in the feces.
Innovators Monograph
You find simplified version here Fibricor Vial